SITE001-0263

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE001 (USA) · Dr. Reyes
consented 2023-01-03

AEs

Serious

Dropout signal

–

Adverse events

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-03-03 (study day 46); relationship: not assessed

mild assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-03-12 (study day 55); relationship: not assessed

severe serious assessed

Grade 4 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-04-26 (study day 100); relationship: N; serious criteria: life-threatening

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-05-12 (study day 116); relationship: not assessed

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-05-31 (study day 135); relationship: not assessed

moderate assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-09-19 (study day 246); relationship: N

Data queries

No data queries.